Genmab kept at neutral by Merrill

Merrill Lynch analyst Erica Whittaker kept Genmab at a neutral rating. The analyst believes that the recent strong performance of Genmab shares reflects the market expectation of an attractive HuMax-CD20 partnership in the coming months. In addition, Genmab is a potential acquisition target. Whittaker's fair value for Genmab is about Dkr 215 per share, which factors in an expected CD20 deal value of $400 million, plus profit share. Shares of the Copenhagen biotechnology company were down Dkr 5.50, or 2.08%, at Dkr 258.50. (Copenhagen: GEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.